NASDAQ:OMER - Omeros Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.10 +0.20 (+1.55 %) (As of 11/21/2018 09:31 AM ET)Previous Close$12.90Today's Range$12.96 - $13.1052-Week Range$8.36 - $27.00Volume12,610 shsAverage Volume981,232 shsMarket Capitalization$617.03 millionP/E Ratio-16.58Dividend YieldN/ABeta3.79 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Its clinical programs include OMS721 that is in Phase III clinical trial for treating immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA), and atypical hemolytic uremic syndrome (aHUS); and in Phase II clinical trial to treat IgA nephropathy, membranous nephropathy, lupus nephritis, and complement component glomerulopathy. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for treating Huntington's diseases and schizophrenia; and OMS405 that is in Phase II clinical trial to treat opioids, nicotine, and alcohol addiction. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; and OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. The company's preclinical programs also include MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HCT-TMA, and age-related macular degeneration; MASP-3-small-molecule inhibitors used for the treatment of PNH and other alternative pathway disorders; G protein-coupled receptor (GPCR) platform, including GPR174 and other Class A orphan GPCRS for treating CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington. Receive OMER News and Ratings via Email Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:OMER Previous Symbol CUSIP68214310 Webwww.omeros.com Phone206-676-5000 Debt Debt-to-Equity RatioN/A Current Ratio2.69 Quick Ratio2.68 Price-To-Earnings Trailing P/E Ratio-16.58 Forward P/E Ratio-5.28 P/E GrowthN/A Sales & Book Value Annual Sales$64.83 million Price / Sales9.90 Cash FlowN/A Price / CashN/A Book Value($1.82) per share Price / Book-7.20 Profitability EPS (Most Recent Fiscal Year)($0.79) Net Income$-53,480,000.00 Net Margins-554.22% Return on EquityN/A Return on Assets-104.70% Miscellaneous Employees173 Outstanding Shares49,010,000Market Cap$617.03 million OptionableOptionable Omeros (NASDAQ:OMER) Frequently Asked Questions What is Omeros' stock symbol? Omeros trades on the NASDAQ under the ticker symbol "OMER." How were Omeros' earnings last quarter? Omeros Co. (NASDAQ:OMER) announced its earnings results on Friday, November, 9th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.77) by $0.04. The biopharmaceutical company had revenue of $4.61 million for the quarter, compared to analyst estimates of $3.07 million. During the same period last year, the company earned ($0.16) earnings per share. View Omeros' Earnings History. When is Omeros' next earnings date? Omeros is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Omeros. What price target have analysts set for OMER? 8 brokers have issued twelve-month target prices for Omeros' stock. Their predictions range from $4.00 to $75.00. On average, they anticipate Omeros' stock price to reach $27.8763 in the next year. This suggests a possible upside of 112.8% from the stock's current price. View Analyst Price Targets for Omeros. What is the consensus analysts' recommendation for Omeros? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Omeros. What are Wall Street analysts saying about Omeros stock? Here are some recent quotes from research analysts about Omeros stock: 1. Maxim Group analysts commented, "Omeros reported 3Q18 with $4.6M in Omidria revenues, up from $1.7M in 2Q18. Omeros reported a net loss for the quarter of ($39.5M), and a cash balance of $55M, excluding the $210M debt offering announced concurrently. OMER shares are down ~20%, in our view, due to a misunderstanding of the financing." (11/9/2018) 2. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (10/9/2018) 3. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We ascribe a total firm value of roughly $2B to Omeros based on OMIDRIA ($806M) and OMS721 ($1.2B). This translates into a target of $34.00 per share, based on 60M fully-diluted shares outstanding as of end-2Q 2019. Risks include: (1) trial delays; (2) adverse clinical results; (3) inability to obtain approval for OMS721 and other candidates; (4) inability to achieve additional market traction with OMIDRIA; and (5) earlier-than-anticipated introduction of OMIDRIA generics in the U.S." (8/6/2018) Has Omeros been receiving favorable news coverage? News articles about OMER stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Omeros earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the stock's share price in the next few days. Are investors shorting Omeros? Omeros saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 9,647,822 shares, an increase of 29.0% from the September 28th total of 7,481,775 shares. Based on an average trading volume of 1,752,572 shares, the days-to-cover ratio is currently 5.5 days. Approximately 21.1% of the shares of the stock are short sold. View Omeros' Current Options Chain. Who are some of Omeros' key competitors? Some companies that are related to Omeros include Ascendis Pharma A/S (ASND), Allakos (ALLK), Blueprint Medicines (BPMC), ACADIA Pharmaceuticals (ACAD), Myokardia (MYOK), Supernus Pharmaceuticals (SUPN), Xencor (XNCR), TESARO (TSRO), Arena Pharmaceuticals (ARNA), Prestige Consumer Healthcare (PBH), Amicus Therapeutics (FOLD), Endocyte (ECYT), Opko Health (OPK), Pacira Pharmaceuticals (PCRX) and Heron Therapeutics (HRTX). Who are Omeros' key executives? Omeros' management team includes the folowing people: Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 59)Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 60)Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 58)Dr. Pamela Pierce Palmer, Co-Founder (Age 55)Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 61) Who are Omeros' major shareholders? Omeros' stock is owned by a number of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (10.84%), BlackRock Inc. (8.15%), Cpwm LLC (1.62%), Foresite Capital Management IV LLC (0.73%), Morgan Stanley (0.58%) and TIAA CREF Investment Management LLC (0.50%). Company insiders that own Omeros stock include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros. Which major investors are selling Omeros stock? OMER stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Cpwm LLC, Wedbush Securities Inc., Credit Suisse AG, Baird Financial Group Inc., Mesirow Financial Investment Management Inc., Nwam LLC and Sheaff Brock Investment Advisors LLC. Company insiders that have sold Omeros company stock in the last year include Marcia S Kelbon and Michael A Jacobsen. View Insider Buying and Selling for Omeros. Which major investors are buying Omeros stock? OMER stock was purchased by a variety of institutional investors in the last quarter, including Foresite Capital Management IV LLC, BlackRock Inc., Teachers Advisors LLC, WealthTrust Axiom LLC, Fox Run Management L.L.C., Alps Advisors Inc., Advisors Asset Management Inc. and MetLife Investment Advisors LLC. View Insider Buying and Selling for Omeros. How do I buy shares of Omeros? Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Omeros' stock price today? One share of OMER stock can currently be purchased for approximately $13.10. How big of a company is Omeros? Omeros has a market capitalization of $617.03 million and generates $64.83 million in revenue each year. The biopharmaceutical company earns $-53,480,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Omeros employs 173 workers across the globe. What is Omeros' official website? The official website for Omeros is http://www.omeros.com. How can I contact Omeros? Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000. MarketBeat Community Rating for Omeros (NASDAQ OMER)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 531 (Vote Outperform)Underperform Votes: 312 (Vote Underperform)Total Votes: 843MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/21/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?